SCHEMBL90934

SCHEMBL90934

Cc1cccc2c1OOC2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
TSHR P16473 1/20 0.32
ACHE P22303 1/20 0.32
BRD4 O60885 1/20 0.31
CREBBP Q92793 1/20 0.31
GAA P10253 1/20 0.31
HTR5A P47898 1/20 0.31
HTR2C P28335 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8576724 0.79 PARP1 (0.37) CYP1A2CYP2A6ALDH1A1HPGDSMN1; SMN2
SCHEMBL3062733 0.77 MAOA (0.37) CYP1A2ALDH1A1HPGDKDM4E
SCHEMBL90913 0.75 ALDH1A1 (0.33) CYP1A2CYP2A6ALDH1A1HPGDSMN1; SMN2
SCHEMBL7567989 0.74 ALDH1A1 (0.36) ALDH1A1HPGDSMN1; SMN2TSHRGAA
SCHEMBL3072437 0.74 BCL2L1 (0.38) ALDH1A1HPGDSMN1; SMN2CA1CA2
SCHEMBL70631 0.74 GABRA1 (0.39) CYP1A2HPGDCA1CA2TSHR
SCHEMBL6871830 0.74 ENPP2 (0.31)
SCHEMBL21938673 0.69 SMN1; SMN2 (0.34) CYP1A2CYP2A6SMN1; SMN2GAAKDM4E
SCHEMBL11272636 0.69
SCHEMBL6907186 0.68 MAOA (0.41) CYP1A2CYP2A6ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299066-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-10-30 US disclosed
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-24 US disclosed
US-8129372-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-03-06 US disclosed
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY Shinonogi & Co., Ltd (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R CYP1A2 2253/4885CYP2A6 2408/4885ALDH1A1 4801/4885
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R CYP1A2 2253/4885CYP2A6 2408/4885ALDH1A1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.